Interesting article stating BioVersys will receive 4.35 million to target Eskape pathogens. We just indicated effectiveness against these? CARB-X might be interested?
BioVersys will initially secure up to $4.35 million from CARB-X to develop the antibiotics. That amount could increase to $10.98 million if the project achieves certain milestones. The CARB-X funding will help support BioVersys’ Lead Optimization program to develop this compound class for difficult-to-treat severe infections, including pneumonia.
Also interesting further down in the article Recce actually get a mention. Not for Eskape but the more recent announcement on MOA.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)